Zhejiang Hisun Pharmaceutical Co Ltd

Zhejiang Hisun Pharmaceutical Co., Ltd. announced that its controlling subsidiary Zhejiang Hisun Animal Health Products Co., Ltd. has received the New Veterinary Drug Registration Certificate for compound fipronil, praziquantel and moxidectin spot-on solution, approved and issued by the Ministry of Agriculture and Rural Affairs. The registration category is Category IV, and the certificate number is 2026 New Veterinary Drug Certificate No. 90. The product was jointly developed by Hisun Animal Health and two other companies, and is used for the prevention and treatment of internal and external parasite infections in cats, including fleas, ticks, heartworm, gastrointestinal nematodes, ear mites and sarcoptic mange. The company stated that the approval will help advance the strategic layout of its veterinary drug segment, but the product still needs to obtain a veterinary drug product approval number before it can be marketed, and it will not have a significant impact on business performance in the short term.

Hisun Pharmaceutical released its 2026 interim report. Total operating revenue was 4.475 billion yuan, and net profit attributable to the parent company was 636 million yuan, an increase of 337 million yuan compared with the same period last year, up 112.82% year on year. Net cash inflow from operating activities was 832 million yuan. The asset-liability ratio was 31.84%, gross margin was 55.58%, ROE was 7.08%, and diluted earnings per share was 0.55 yuan. The company had 48,800 shareholders, and the top ten shareholders held 45.81% of the total share capital.

Hisun Pharmaceutical's wholly-owned subsidiary Hisun Hangzhou has received approval from the US FDA for its Abbreviated New Drug Application for Fludarabine Phosphate Injection. The drug, with a strength of 50 milligrams per 2 milliliters, or 25 milligrams per milliliter, is a nucleoside metabolic inhibitor indicated for combination therapy in adults with B-cell chronic lymphocytic leukemia.

Hisun Pharmaceutical announced that it recently received the Drug Registration Certificate for Letermovir tablets approved and issued by the National Medical Products Administration. The drug is indicated for cytomegalovirus seropositive adult and pediatric patients undergoing allogeneic hematopoietic stem cell transplantation, for the prevention of cytomegalovirus infection and cytomegalovirus disease. The company's Letermovir tablets were approved as a Category 4 chemical drug, which is deemed to have passed the consistency evaluation.

Hisun Pharmaceutical released its first-half earnings forecast, expecting net profit of 600 million to 650 million yuan, a year-on-year increase of 100.62% to 117.34%. The stock closed at 10.77 yuan today, up 3.26%, with a daily turnover rate of 2.82% and a trading volume of 355 million yuan. The share price has risen 2.28% over the past five days, while major funds saw a net outflow of 9.3921 million yuan over the same period. The latest margin trading balance stands at 790 million yuan, of which the financing balance is 788 million yuan, up 0.15% from the previous period.

Hisun Pharmaceutical has signed an exclusive product license and collaboration agreement with Aitia Shanghai Pharmaceuticals. The deal grants Hisun the rights to develop, register, manufacture, and commercialize the Class 1 innovative chemical drug TISA-818 systemic formulation in mainland China, Hong Kong, and Macau, making it the marketing authorization holder in the region. The company will pay an upfront fee of 45 million yuan, with cumulative development milestone payments capped at 100 million yuan, and sales milestone rewards based on a percentage of annual net sales, up to a maximum of 200 million yuan. TISA-818 is a novel mechanism drug that modulates immune responses through multiple targets and pathways, offering anti-inflammatory effects without immunosuppression. It has completed a Phase I clinical trial for pulmonary fibrosis in Europe and a Phase IIa trial for acute respiratory distress syndrome in China, demonstrating promising therapeutic potential.